Premium
Treatment of malignant lymphomas with methyl ester of streptonigrin (NSC 45384)
Author(s) -
Rivers Shirley L.,
Whittington Richard M.,
Medrek Theodore J.
Publication year - 1966
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(196610)19:10<1377::aid-cncr2820191008>3.0.co;2-l
Subject(s) - medicine , leukopenia , chronic lymphocytic leukemia , nausea , mycosis fungoides , lymphoma , gastroenterology , drug , vomiting , leukemia , chemotherapy , pharmacology
Forty three patients with lymphomas or chronic lymphocytic leukemia were treated with intravenous methyl ester of streptonigrin. The total dose for a single course ranged from 0.05 to 0.3 mg/kg, the optimum being 0.1 mg/kg. Thirty patients lived for at least 6 weeks and were considered evaluable. Nine objective remissions were seen in Hodgkin's disease, 5 in lymphocytic lymphoma, 2 in mycosis fungoides and 4 in chronic lymphocytic leukemia. The other 10 patients showed some evidence of favorable drug effect. Immediate toxic reactions were mainly nausea and emesis, though 3 patients had striking but reversible hypotension at the time the drug was administered. Thrombocytopenia occurred in 24 patients and leukopenia in 15 patients. Marrow suppression was generally reversible in 2 to 3 weeks.